From 18–21 May 2024, Nature Reviews Gastroenterology & Hepatology was back at Digestive Disease Week (DDW) in Washington DC, USA, alongside >14,300 attendees both in person and virtually, according to the organizers.

A wide array of sessions were available, covering basic, translational and clinical science in gastroenterology and hepatology. For basic and translational sciences, talks on the gut microbiome were popular and plentiful, including sessions on the links between the exposome and microbiome, and one dedicated to the ‘dark matter’ of the gut microbiome, bacteriophages and fungi. Clinical sessions addressed topics such as ‘IBS in IBD’ and new approaches in colorectal cancer screening (including insights into the use of artificial intelligence and novel blood- and stool-based tests). The clinical late-breaker session featured positive interim phase II results for survodutide in metabolic dysfunction-associated steatohepatitis and efficacy for apraglutide in short bowel syndrome with intestinal failure reported in the phase III STARS trial, among others.

据组织者称，2024 年 5 月 18 日至 21 日，Nature Reviews Gastroenterology & Hepatology 重返美国华盛顿特区消化疾病周 (DDW)，现场和虚拟与会者人数超过 14,300 人。

会议范围广泛，涵盖胃肠病学和肝病学的基础科学、转化科学和临床科学。对于基础科学和转化科学，关于肠道微生物组的讲座很受欢迎且数量众多，包括关于暴露组和微生物组之间联系的会议，以及专门讨论肠道微生物组、噬菌体和真菌的“暗物质”的会议。临床会议讨论了“IBD 中的 IBS”和结直肠癌筛查新方法等主题（包括对人工智能和新型血液和粪便测试的使用的见解）。临床后期会议的特点是 survodutide 在代谢功能障碍相关脂肪性肝炎中的 II 期中期结果，以及在 III 期 STARS 试验中报告的 apraglutide 在短肠综合征伴肠衰竭中的疗效等。